Last reviewed · How we verify
LErafAON
At a glance
| Generic name | LErafAON |
|---|---|
| Sponsor | INSYS Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer (PHASE1)
- Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors (PHASE1)
- Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LErafAON CI brief — competitive landscape report
- LErafAON updates RSS · CI watch RSS
- INSYS Therapeutics Inc portfolio CI